Clinical Scorecard: FDA clears targeted cholangiocarcinoma therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Cholangiocarcinoma |
| Key Mechanisms | Kinase inhibitor targeting fibroblast growth factor receptor 2 gene fusion or rearrangement |
| Target Population | Adults with unresectable, locally advanced or metastatic cholangiocarcinoma previously treated with chemotherapy or chemoimmunotherapy |
| Care Setting | Oncology |
Key Highlights
- Lirafugratinib approved for previously treated unresectable cholangiocarcinoma
- Efficacy assessed in the REFOCUS trial with 116 patients
- 46% objective response rate observed
- Median response duration of 11.8 months
- Safety warnings include ocular toxicity and hyperphosphatemia
Guideline-Based Recommendations
Diagnosis
- Diagnosis of unresectable or metastatic cholangiocarcinoma confirmed
Management
- Administer lirafugratinib at 70 mg once daily until disease progression or unacceptable toxicity
Monitoring & Follow-up
- Monitor for ocular toxicity, hyperphosphatemia, and embryo-fetal toxicity
Risks
- Potential for ocular toxicity and soft tissue mineralization
Patient & Prescribing Data
Adults with previously treated unresectable cholangiocarcinoma
Lirafugratinib is a targeted therapy with a significant response rate in this patient population
Clinical Best Practices
- Consider genetic testing for fibroblast growth factor receptor gene fusions or rearrangements
- Utilize independent review for assessing treatment response
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
